335 related articles for article (PubMed ID: 35902641)
1. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.
Dongye Z; Li J; Wu Y
Br J Cancer; 2022 Nov; 127(9):1584-1594. PubMed ID: 35902641
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
4. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
Vollmer J
Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
Yao Y; Li J; Qu K; Wang Y; Wang Z; Lu W; Yu Y; Wang L
Cancer Immunol Immunother; 2023 May; 72(5):1103-1120. PubMed ID: 36326892
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Toll-like receptor 9 activation.
Krieg AM
Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
[TBL] [Abstract][Full Text] [Related]
8. Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy.
Jin Y; Zhuang Y; Dong X; Liu M
Expert Rev Anticancer Ther; 2021 Aug; 21(8):841-851. PubMed ID: 33831324
[TBL] [Abstract][Full Text] [Related]
9. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
Hanagata N
Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
[TBL] [Abstract][Full Text] [Related]
10. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
11. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
12. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
Assaf A; Esteves H; Curnow SJ; Browning MJ
Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
Front Immunol; 2020; 11():1075. PubMed ID: 32547560
[TBL] [Abstract][Full Text] [Related]
14. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U; Scheulen ME; von Bergwelt-Baildon MS; Weihrauch MR
Expert Opin Investig Drugs; 2011 Mar; 20(3):361-72. PubMed ID: 21254877
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy.
Chang LS; Leng CH; Yeh YC; Wu CC; Chen HW; Huang HM; Liu SJ
Mol Cancer; 2014 Mar; 13():60. PubMed ID: 24642245
[TBL] [Abstract][Full Text] [Related]
17. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Murad YM; Clay TM; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1257-66. PubMed ID: 17696823
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes.
Sumiya K; Izumi H; Sakurai K
ACS Appl Bio Mater; 2023 Feb; 6(2):774-783. PubMed ID: 36632777
[TBL] [Abstract][Full Text] [Related]
19. Toll-Like Receptor 9 Agonists in Cancer.
Karapetyan L; Luke JJ; Davar D
Onco Targets Ther; 2020; 13():10039-10060. PubMed ID: 33116588
[TBL] [Abstract][Full Text] [Related]
20. Antiinfective applications of toll-like receptor 9 agonists.
Krieg AM
Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
